Wednesday, May 04, 2016 11:10:06 AM
Here's a concern, if neither T. or C. Ichim is employed anymore by RGBP, then RGBP no longer has an in house scientist to carry ongoing research forward and we are back in the pre 2015 scenario which concerns me.
Granted, the relationship with NIH / NCATS and Dr. Kesari under contract to perform testing on DCellVax and maybe tCellVax is great, but without an internal scientist doing other day to day research coordination, I think the company will not have the same potential of bringing all this forward in an efficient manner. And the loss of the two scientists whose research and IP led to the current pipeline is not an encouraging sign.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM